Renin-angiotensin system blockade and diabetes: Moving the adipose organ from the periphery to the center

Kidney International

Volumn 74, Issue 7, 2008, Pages 851-853

  Lenz, Oliver ^a   Fornoni, Alessia ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ADIPOCYTOKINE; ADIPONECTIN RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE TRANSPORTER 4; IRBESARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; TELMISARTAN; TOLL LIKE RECEPTOR 4;

ADIPOCYTE; ADIPOSE TISSUE; CELL COUNT; CELL DIFFERENTIATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DRUG INHIBITION; GLUCONEOGENESIS; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 51849158818     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.391     Document Type: Note

References (14)

1. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-826.
2. Tomono Y, Iwai M, Inaba S et al. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008; 21: 206-212.
3. Shiuchi T, Iwai M, Li HS et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-1010.
4. Henriksen EJ, Jacob S, Kinnick TR et al. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-890.
5. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007; 580: 31-37.
6. Chan P, Liu IM, Tzeng TF et al. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin- induced diabetic rats. Diabetes Obes Metab 2007; 9: 39-49.
7. Folli F, Kahn CR, Hansen H et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-2169.
8. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
9. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
10. Okamoto Y, Kihara S, Funahashi T et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267-278.
11. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
12. Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656.
13. Lee MH, Song HK, Ko GJ et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008; 74: 890-900.
14. Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.